Mild versus strong anti-inflammatory therapy during early sepsis in mice: A matter of life and death

Critical Care Medicine

Volumn 39, Issue 6, 2011, Pages 1275-1281

  Van Den Berg, Jan Willem ^a   Van Der Zee, Marten ^a   De Bruin, Ron W F ^a   Van Holten Neelen, Conny ^a   Bastiaans, Jeroen ^a   Nagtzaam, Nicole M A ^a   Ijzermans, Jan N M ^a   Benner, Robbert ^a   Dik, Willem A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

bacterial response; corticosteroids; inflammation; sepsis; therapy

Indexed keywords

CORTICOSTERONE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; DEXAMETHASONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EOTAXIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL LOAD; BLOOD; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CORTICOSTERONE BLOOD LEVEL; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; GENE EXPRESSION; HOST RESISTANCE; INFLAMMATION; KIDNEY; LIVER; LOW DRUG DOSE; LUNG; MALE; MONOCYTE; MORTALITY; MOUSE; NONHUMAN; PERITONEAL FLUID; PLASMA; PRIORITY JOURNAL; RESPIRATORY BURST; SEPSIS; SURVIVAL TIME;

EID: 79957649524     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31820edf75     Document Type: Article

References (53)

1. Dombrovskiy VY, Martin AA, Sunderram J: Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003. Crit Care Med 2007; 35:1244-1250. (Pubitemid 46642649)
2. Bone RC: Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24:1125-1128.
3. Haveman JW, Muller Kobold AC, Tervaert JW, et al: The central role of monocytes in the pathogenesis of sepsis: Consequences for immunomonitoring and treatment. Neth J Med 1999; 55:132-141. (Pubitemid 29389663)
4. Rittirsch D, Flierl MA, Ward PA: Harmful molecular mechanisms in sepsis. Nat Rev 2008; 8:776-787.
5. Osuchowski MF, Welch K, Siddiqui J, et al: Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006; 177:1967-1974.
6. Hotchkiss RS, Coopersmith CM, McDunn JE, et al: The sepsis seesaw: Tilting toward immunosuppression. Nat Med 2009; 15: 496-497.
7. Döcke WD, Randow F, Syrbe U, et al: Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3:678-681. (Pubitemid 27264980)
8. Williams MA, Withington S, Newland AC, et al: Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colonystimulating factor ex vivo. J Infect Dis 1998; 178:1421-1433.
9. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554. (Pubitemid 36437931)
10. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310. (Pubitemid 32641789)
11. Schumer W: Steroids in the treatment of clinical septic shock. Ann Surg 1976; 184: 333-341.
12. Sprung CL, Annane D, Keh D, et al: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124.
13. Bone RC, Fisher CJ Jr, Clemmer TP, et al: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-658. (Pubitemid 17138189)
14. Tracey KJ, Fong Y, Hesse DG, et al: Anticachectin/ TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-664. (Pubitemid 18005583)
15. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229:869-871. (Pubitemid 16246587)
16. Eskandari MK, Bolgos G, Miller C, et al: Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992; 148:2724-2730.
17. Remick D, Manohar P, Bolgos G, et al: Blockade of tumor necrosis factor reduces lipopolysaccharide lethality, but not the lethality of cecal ligation and puncture. Shock 1995; 4:89-95.
18. Cameron EM, Zhuang J, Menconi MJ, et al: Dantrolene, an inhibitor of intracellular calcium release, fails to increase survival in a rat model of intra-abdominal sepsis. Crit Care Med 1996; 24:1537-1542. (Pubitemid 26313757)
19. Fisher CJ Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-1702. (Pubitemid 26193621)
20. Reinhart K, Menges T, Gardlund B, et al: Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001; 29:765-769. (Pubitemid 32299714)
21. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709. (Pubitemid 32204987)
22. Annane D, Bellissant E, Bollaert PE, et al: Corticosteroids in the treatment of severe sepsis and septic shock in adults: A systematic review. JAMA 2009; 301:2362-2375.
23. van den Berg JW, Dik WA, van der Zee M, et al: The beta-human chorionic gonadotropinrelated peptide LQGV reduces mortality and inflammation in a murine polymicrobial sepsis model. Crit Care Med 2011, 39:126-134.
24. Wichterman KA, Baue AE, Chaudry IH: Sepsis and septic shock-a review of laboratory models and a proposal. J Surg Res 1980; 29:189-201. (Pubitemid 10039498)
25. Osuchowski MF, Connett J, Welch K, et al: Stratification is the key: Inflammatory biomarkers accurately direct immunomodulatory therapy in experimental sepsis. Crit Care Med 2009; 37:1567-1573.
26. Osuchowski MF, Siddiqui J, Copeland S, et al: Sequential ELISA to profile multiple cytokines from small volumes. J Immunol Methods 2005; 302:172-181. (Pubitemid 41111884)
27. van den Berg HR, Khan NA, van der Zee M, et al: Synthetic oligopeptides related to the [beta]- subunit of human chorionic gonadotropin attenuate inflammation and liver damage after (trauma) hemorrhagic shock and resuscitation. Shock 2009; 31:285-291.
28. Khan NA, Susa D, van den Berg JW, et al: Amelioration of renal ischaemia-reperfusion injury by synthetic oligopeptides related to human chorionic gonadotropin. Nephrol Dial Transplant 2009; 24:2701-2708.
29. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150. (Pubitemid 36056721)
30. Goss CH, Brower RG, Hudson LD, et al: Incidence of acute lung injury in the United States. Crit Care Med 2003; 31:1607-1611. (Pubitemid 36714211)
31. Shen L, Mo H, Cai L, et al: Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock 2009; 31:500-506.
32. Annane D, Cavaillon JM: Corticosteroids in sepsis: From bench to bedside? Shock 2003; 20:197-207.
33. Sessler CN: Steroids for septic shock: Back from the dead? (Con). Chest 2003; 123(Suppl 5):482S-489S. (Pubitemid 36549818)
34. Balk RA: Steroids for septic shock: Back from the dead? (Pro). Chest 2003; 123(Suppl 5): 490S-499S. (Pubitemid 36549819)
35. Villa P, Sartor G, Angelini M, et al: Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin. Clin Diagn Lab Immunol 1995; 2:549-553.
36. Gadina M, Bertini R, Mengozzi M, et al: Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid- sensitive and glucocorticoidresistant models of endotoxic shock. J Exp Med 1991; 173:1305-1310.
37. Hubbard WJ, Choudhry M, Schwacha MG, et al: Cecal ligation and puncture. Shock 2005; 24(Suppl 1):52-57.
38. Hollenbach SJ, DeGuzman LR, Bellamy RF: Early administration of methylprednisolone promotes survival in rats with intra-abdominal sepsis. Circ Shock 1986; 20:161-168. (Pubitemid 17176333)
39. Netea MG, van der Meer JW, van Deuren M, et al: Proinflammatory cytokines and sepsis syndrome: Not enough, or too much of a good thing? Trends Immunol 2003; 24: 254-258. (Pubitemid 36555964)
40. Mü ller I, Munder M, Kropf P, et al: Polymorphonuclear neutrophils and T lymphocytes: Strange bedfellows or brothers in arms? Trends Immunol 2009; 30:522-530.
41. Conlan JW: Critical roles of neutrophils in host defense against experimental systemic infections of mice by Listeria monocytogenes, Salmonella typhimurium, and Yersinia enterocolitica. Infect Immun 1997; 65: 630-635. (Pubitemid 27053235)
42. van der Zee M, Dik WA, Kap YS, et al: Synthetic human chorionic gonadotropinrelated oligopeptides impair early innate immune responses to Listeria monocytogenes in mice. J Infect Dis 2010; 201: 1072-1080.
43. Cao L, Hudson CA, Lawrence DA: Immune changes during acute cold/restraint stressinduced inhibition of host resistance to Listeria. Toxicol Sci 2003; 74:325-334. (Pubitemid 36958301)
44. Peck-Palmer OM, Unsinger J, Chang KC, et al: Deletion of MyD88 markedly attenuates sepsis-induced T and B lymphocyte apoptosis but worsens survival. J Leukoc Biol 2008; 83:1009-1018. (Pubitemid 351959882)
45. Friedland JS, Porter JC, Daryanani S, et al: Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit. Crit Care Med 1996; 24:1775-1781. (Pubitemid 26382917)
46. Hack CE, De Groot ER, Felt-Bersma RJ, et al: Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74:1704-1710. (Pubitemid 19251549)
47. Riedemann NC, Neff TA, Guo RF, et al: Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol 2003; 170:503-507. (Pubitemid 36026177)
48. Remick DG, Bolgos G, Copeland S, et al: Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect Immun 2005; 73:2751-2757. (Pubitemid 40570341)
49. Deutschman CS, Cereda M, Ochroch EA, et al: Sepsis-induced cholestasis, steatosis, hepatocellular injury, and impaired hepatocellular regeneration are enhanced in interleukin- 6-/- mice. Crit Care Med 2006; 34: 2613-2620. (Pubitemid 44413061)
50. Newcomb D, Bolgos G, Green L, et al: Antibiotic treatment influences outcome in murine sepsis: mediators of increased morbidity. Shock 1998; 10:110-117. (Pubitemid 128463842)
51. Li Y, Cui X, Li X, et al: Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model: Risk and corticosteroids in sepsis. Intensive Care Med 2008; 34:568-577. (Pubitemid 351623024)
52. Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to human studies revisited. FASEB J 2008; 22:659-661. (Pubitemid 351348146)
53. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327